Dipeptidyl peptidase-4 inhibitors increase risk of IBD
This is a preview of subscription content, log in to check access.
Abrahami D, et al. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ 2018: k872, No. 360, 21 Mar 2018. Available from: URL: https://doi.org/10.1136/bmj.k872CrossRefGoogle Scholar